Michael Larj
Pulmonary Disease · Rochester, NYNPI 1679507099
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $214,993 of the $229,005 with a category attached, or 93.9%. AstraZeneca accounts for 75.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $77,526 and has fallen 92.1% since, to $6,140 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $970.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$173K
- GSK$50K
- Mylan Specialty L.p.$6K
- Sanofi$226
- Mallinckrodt Hospital Products Inc.$106
Across 2 payments — averaging $305.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$611
What the payments were for
- Consulting fees$3,2801%
- Speaking & faculty fees$214,99394%
- Travel & lodging$4,4692%
- Food & beverage$6,2633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 179 | $172,618 |
| GSK | 46 | $50,108 |
| Mylan Specialty L.p. | 8 | $5,948 |
| Sanofi | 2 | $226 |
| Mallinckrodt Hospital Products Inc. | 1 | $106 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$229,005 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,973 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $4,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $172,618 | $16,32036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Rochester
- R WhiteRochester$242K
- Daniel LachantRochester$141K
- Jason LyonsRochester$55K
- Christina BachRochester$53K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.